(XPH) SPDR S&P Pharmaceuticals - Ratings and Ratios
Pharmaceuticals, Drugmakers, Generics, Biotech
Description: XPH SPDR S&P Pharmaceuticals
The SPDR S&P Pharmaceuticals ETF (XPH) is a healthcare-focused exchange-traded fund listed on the NYSE ARCA exchange. As a sector-specific ETF, it tracks the S&P Pharmaceuticals Select Industry Index, providing investors with exposure to the pharmaceutical industry.
Key performance indicators (KPIs) for XPH include its Assets Under Management (AUM), currently standing at $153.12 million USD. The funds liquidity is relatively stable, with an average trading volume of 21,900 shares. The ETFs price movements are moderately correlated with the broader market, as indicated by its beta of 0.760.
The pharmaceutical industry is driven by several key economic factors, including government regulations, patent expirations, and research and development (R&D) investments. The industry is also influenced by demographic trends, such as aging populations and the prevalence of chronic diseases. Additionally, the sector is subject to intense competition, with companies competing on factors like pricing, product innovation, and marketing efforts.
To evaluate XPHs performance, investors should consider metrics like the funds tracking error, expense ratio, and dividend yield. The ETFs holdings are likely to be weighted towards large-cap pharmaceutical companies with strong R&D pipelines and stable cash flows. Investors should also monitor industry trends, such as the impact of generic competition, regulatory changes, and advancements in biotechnology.
From a trading perspective, XPHs price action can be analyzed using technical indicators like moving averages and relative strength index (RSI). The funds current price is near its 52-week high, suggesting a strong uptrend. However, investors should be cautious of potential risks, such as market volatility and sector rotation.
XPH ETF Overview
| Market Cap in USD | 170m |
| Category | Health |
| TER | 0.35% |
| IPO / Inception | 2006-06-19 |
XPH ETF Ratings
| Growth Rating | -3.71% |
| Fundamental | - |
| Dividend Rating | 53.1% |
| Return 12m vs S&P 500 | -11.4% |
| Analyst Rating | - |
XPH Dividends
| Dividend Yield 12m | 1.33% |
| Yield on Cost 5y | 1.43% |
| Annual Growth 5y | 22.61% |
| Payout Consistency | 91.1% |
| Payout Ratio | % |
XPH Growth Ratios
| Growth Correlation 3m | 91.5% |
| Growth Correlation 12m | -29.4% |
| Growth Correlation 5y | -32.7% |
| CAGR 5y | 4.54% |
| CAGR/Max DD 3y | 0.19 |
| CAGR/Mean DD 3y | 0.72 |
| Sharpe Ratio 12m | 1.10 |
| Alpha | -10.65 |
| Beta | 0.866 |
| Volatility | 15.90% |
| Current Volume | 105.6k |
| Average Volume 20d | 45.9k |
| Stop Loss | 44.6 (-3%) |
| Signal | -2.10 |
What is the price of XPH shares?
Over the past week, the price has changed by -3.36%, over one month by -0.17%, over three months by +10.71% and over the past year by +5.33%.
Is SPDR S&P Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XPH is around 44.28 USD . This means that XPH is currently overvalued and has a potential downside of -3.74%.
Is XPH a buy, sell or hold?
What are the forecasts/targets for the XPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 49.7 | 8% |
Last update: 2025-09-15 04:47
XPH Fundamental Data Overview
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 USD
Beta = 0.79
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 169.9m USD (169.9m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 169.9m)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 169.9m / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(169.9m)/V(0.0) * Re(9.21%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for XPH ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle